274 related articles for article (PubMed ID: 29204688)
1. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
Völler S; Pichlmeier U; Zens A; Hempel G
Cancer Chemother Pharmacol; 2018 Feb; 81(2):305-314. PubMed ID: 29204688
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
Sassen SD; Mathôt RA; Pieters R; Kloos RQ; de Haas V; Kaspers GJ; van den Bos C; Tissing WJ; Te Loo M; Bierings MB; Kollen WJ; Zwaan CM; van der Sluis IM
Haematologica; 2017 Mar; 102(3):552-561. PubMed ID: 28250007
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar
Würthwein G; Lanvers-Kaminsky C; Hempel G; Gastine S; Möricke A; Schrappe M; Karlsson MO; Boos J
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):955-963. PubMed ID: 28349335
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
van der Sluis IM; de Groot-Kruseman H; Te Loo M; Tissing WJE; van den Bos C; Kaspers GJL; Bierings M; Kollen WJW; König T; Pichlmeier U; Kühnel HJ; Pieters R
Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
Würthwein G; Lanvers-Kaminsky C; Siebel C; Gerß J; Möricke A; Zimmermann M; Stary J; Smisek P; Schrappe M; Rizzari C; Zucchetti M; Hempel G; Wicha SG; Boos J;
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):289-300. PubMed ID: 33595793
[TBL] [Abstract][Full Text] [Related]
7. Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
Bauch T; Hempel G
Br J Haematol; 2024 Jun; 204(6):2324-2331. PubMed ID: 38494194
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
9. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
[TBL] [Abstract][Full Text] [Related]
10. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
[TBL] [Abstract][Full Text] [Related]
11. A population pharmacokinetic model for pegylated-asparaginase in children.
Hempel G; Müller HJ; Lanvers-Kaminsky C; Würthwein G; Hoppe A; Boos J
Br J Haematol; 2010 Jan; 148(1):119-25. PubMed ID: 19821822
[TBL] [Abstract][Full Text] [Related]
12. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
14. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia.
Brigitha LJ; Mondelaers V; Liu Y; Albertsen BK; Zalewska-Szewczyk B; Rizzari C; Kotecha RS; Pieters R; Huitema ADR; van der Sluis IM
Pharm Res; 2024 Apr; 41(4):711-720. PubMed ID: 38538970
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
Vieira Pinheiro JP; Ahlke E; Nowak-Göttl U; Hempel G; Müller HJ; Lümkemann K; Schrappe M; Rath B; Fleischhack G; Mann G; Boos J
Br J Haematol; 1999 Feb; 104(2):313-20. PubMed ID: 10050714
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
18. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
19. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
